摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-(cyclopropylmethyl)-2-methoxyethanesulfonamide

中文名称
——
中文别名
——
英文名称
N-(cyclopropylmethyl)-2-methoxyethanesulfonamide
英文别名
——
N-(cyclopropylmethyl)-2-methoxyethanesulfonamide化学式
CAS
——
化学式
C7H15NO3S
mdl
——
分子量
193.27
InChiKey
ZEMJGPCDZGLCSP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.1
  • 重原子数:
    12
  • 可旋转键数:
    6
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    63.8
  • 氢给体数:
    1
  • 氢受体数:
    4

文献信息

  • Ether Compounds for Treatment of Complement Mediated Disorders
    申请人:Achillion Pharmaceuticals, Inc.
    公开号:US20150239920A1
    公开(公告)日:2015-08-27
    Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R 12 or R 13 on the A group is an ether (R 32 ) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.
    提供了有关制备抑制补体因子D的化合物、使用方法和制备过程,所述化合物包括具有式I的化合物,或其药用可接受的盐或组合物,其中A组上的R12或R13是醚(R32)。本文描述的抑制剂靶向因子D并在替代性补体途径的早期和关键点上抑制或调节补体级联,并减少因子D调节经典和凝集素补体途径的能力。本文描述的因子D抑制剂能够减少过度激活的补体,这与某些自身免疫、炎症和神经退行性疾病、缺血再灌注损伤和癌症有关。
  • ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS
    申请人:Achillion Pharmaceuticals, Inc.
    公开号:US20160362433A1
    公开(公告)日:2016-12-15
    Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R 12 or R 13 on the A group is an ether (R 32 ) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement.
  • US9732104B2
    申请人:——
    公开号:US9732104B2
    公开(公告)日:2017-08-15
查看更多